

October 1, 2008

**ONO PHARMACEUTICAL CO., LTD.**

Public Relations Phone: +81-6-6263-5670

**Announcement on Results of Phase II / III Clinical Study in Japan  
with Arocyte for Injection for Treatment of Acute Ischemic Stroke**

The development of Arocyte for Injection (Development Code: ONO-2506) for the treatment of acute ischemic stroke has been pursued in and outside Japan, and today Ono Pharmaceutical Co., Ltd. (Osaka, Japan) announced that the key code of Phase II / III clinical study conducted in Japan was broken and that the results of the study revealed that the efficacy is not as expected.

We will make a decision as to whether we continue the development of this drug based on further analysis of the results obtained this time in detail, and the decision will be announced in the near future.

The development of the drug outside Japan is pursued by Merck & Co. of the U.S., and it is in Phase II study.